SCHEMBL29854331

SCHEMBL29854331

FC(F)(F)c1ccc(Oc2cccc3ccccc23)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.52
SLC6A4 P31645 2/20 0.48
L3MBTL1 Q9Y468 3/20 0.45
MEN1 O00255 2/20 0.45
LMNA P02545 2/20 0.45
KMT2A Q03164 2/20 0.45
MITF O75030 1/20 0.45
POLB P06746 1/20 0.45
MAPT P10636 3/20 0.44
HTT P42858 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
HTR1A P08908 2/20 0.43
RAB9A P51151 1/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8589772 0.87 HPGD (0.44) HPGDSLC6A4L3MBTL1MEN1LMNA
SCHEMBL2078871 0.85 L3MBTL1 (0.54) HPGDSLC6A4L3MBTL1MEN1LMNA
SCHEMBL28638978 0.83 L3MBTL1 (0.52) HPGDSLC6A4L3MBTL1LMNAKMT2A
SCHEMBL17147389 0.83 MAPT (0.46) HPGDSLC6A4L3MBTL1MEN1LMNA
SCHEMBL22558989 0.82 L3MBTL1 (0.47) HPGDL3MBTL1MEN1LMNAKMT2A
SCHEMBL10594947 0.82 TRPV1 (0.50) HPGDL3MBTL1RAB9A
SCHEMBL9643981 0.80 ESR1 (0.41) SLC6A4L3MBTL1MEN1LMNAKMT2A
SCHEMBL29148791 0.80 L3MBTL1 (0.50) HPGDL3MBTL1MEN1LMNAKMT2A
SCHEMBL441860 0.79 KCNA3 (0.58) HPGDL3MBTL1MEN1LMNAKMT2A
SCHEMBL29860318 0.79 KCNA3 (0.58) HPGDL3MBTL1MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12103902-B2 Bicyclic compounds VIVACE THERAPEUTICS, INC. (US) 2024-10-01 US disclosed
US-20240025913-A1 TERTIARY CARBOXAMIDE COMPOUNDS VIVACE THERAPEUTICS, INC. 2024-01-25 US disclosed
US-20220298102-A1 BICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2022-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298102-A1 BICYCLIC COMPOUNDS YAP1, TEAD2, TEAD3 HPGD 1041/4885SLC6A4 4840/4885L3MBTL1 1959/4885
US-20240025913-A1 TERTIARY CARBOXAMIDE COMPOUNDS YAP1, TFAM, PC HPGD 1219/4885SLC6A4 4795/4885L3MBTL1 1921/4885
US-12103902-B2 Bicyclic compounds YAP1, TEAD2, TEAD3 HPGD 898/4885SLC6A4 4788/4885L3MBTL1 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.